Clean Science and Technology Limited reported a consolidated net profit of ₹733.50 million for the quarter ended June 30, 2026 (Q1FY26), marking a 4.7% decline from ₹700.63 million in the corresponding period of FY25. Despite the dip in bottom-line profitability, the company achieved a 10.5% year-on-year increase in revenue from operations, which stood at ₹2,684.32 million compared to ₹2,428.69 million in Q1FY25. The divergence between revenue growth and profit contraction highlights margin pressure primarily stemming from increased material costs and employee benefits expenses during the quarter.

The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on August 1, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subjected to a limited review by the statutory auditors, Price Waterhouse Chartered Accountants LLP. Additionally, the Board declared a final dividend for equity shareholders, with the record date fixed for September 5, 2026, and payment scheduled for September 30, 2026. The Register of Members will remain closed from September 6 to September 12, 2026, for the purpose of determining dividend entitlements and conducting the 23rd Annual General Meeting (AGM).

Financial Performance Overview

Consolidated total income rose to ₹2,906.50 million from ₹2,562.95 million in Q1FY25, fueled by both operational revenue growth and a significant jump in other income to ₹222.18 million from ₹134.26 million. However, total expenses expanded more sharply to ₹1,930.99 million, up from ₹1,617.46 million in the prior year quarter. Cost of materials consumed increased by 36.3% to ₹1,268.48 million, while employee benefits expense rose 9.3% to ₹166.28 million. The company noted that the lower employee benefits expense in the previous quarter (Q4FY26) was due to executive directors voluntarily foregoing performance bonuses, making the current quarter’s comparison less favorable.

Standalone results showed a net profit of ₹732.91 million, down 4.3% from ₹765.74 million in Q1FY25. Standalone revenue from operations decreased 5.8% to ₹2,071.04 million from ₹2,199.06 million. The standalone other income surged significantly to ₹213.85 million from ₹129.24 million, partially offsetting the decline in core operational revenue.

Strategic Developments and Governance

In a significant strategic move, Clean Fino-Chem Limited, a wholly-owned subsidiary of Clean Science, entered into a long-term collaboration agreement with Geneus Chem AG on July 16, 2026. The partnership involves the manufacturing and exclusive worldwide supply of advanced grades of HALS (Hindered Amine Light Stabilizers) products. Under the terms, Geneus Chem AG will issue warrants to Clean Fino-Chem, exercisable within four years, allowing the subsidiary to acquire a 25% stake in Geneus Chem AG on a fully diluted basis upon exercise.

The Board also co-opted Mr. Krishnakumar Satyanarain Saboo as an Additional Director, effective August 1, 2026. He is recommended for appointment as Whole-time Director for a five-year term ending July 31, 2031, subject to shareholder approval at the upcoming AGM. Mr. Saboo, who has over 37 years of experience in production planning and process improvement, has been associated with the company for more than 11 years and currently serves as Group President (Operations). Additionally, the Board approved the incorporation of a wholly-owned foreign subsidiary in the Netherlands through Clean Fino-Chem Limited, with an initial capital equivalent to EUR 50,000, to engage in the trading and distribution of specialty chemicals.

What the Numbers Show

The financial data reveals a distinct shift in cost structure. While revenue grew robustly at 10.5%, the cost of materials consumed grew at a faster rate of 36.3%, indicating potential input cost inflation or a shift in product mix towards lower-margin items. This was exacerbated by a normalization of employee benefit expenses after the one-time bonus reversal in the preceding quarter. However, the substantial rise in other income (₹222.18 million vs ₹134.26 million) provided a crucial buffer, preventing a sharper decline in net profit. Investors should monitor whether the new HALS product collaboration with Geneus Chem AG can help diversify revenue streams and improve margins in subsequent quarters, as the current standalone revenue contraction suggests headwinds in existing business lines.

Clean Science and Technology Limited reported its highest-ever consolidated sales in Q1FY27, reaching ₹2,684.32 million, a 10.5% year-on-year increase from ₹2,428.69 million in Q1FY26. While standalone revenue declined 5.8% to ₹2,071.04 million due to global headwinds, the consolidated group delivered robust growth driven by its subsidiary, Clean Fino-Chem Limited. Consolidated net profit rose 4.7% to ₹733.50 million, compared to ₹700.63 million in the prior year. The Board of Directors approved these unaudited results on August 1, 2026, following a limited review by statutory auditors Price Waterhouse Chartered Accountants LLP.

Financial Performance

The divergence between standalone and consolidated figures highlights the growing contribution of subsidiaries. Standalone EBITDA margin contracted to 42.7% from 46.4% in Q1FY26, while consolidated EBITDA margin stood at 36.5%, down from 41.6%. However, consolidated profit before tax (PBT) grew 3.2% to ₹975.51 million. Other income provided a significant buffer, contributing ₹213.85 million to standalone total income, up from ₹129.24 million previously.

Raw material costs accounted for 34.6% of standalone revenue, up from 32.5% in Q1FY26. Power and fuel costs rose to 10.8% from 9.2%. Despite these pressures, the company maintained a zero-debt status and strong return on capital employed (RoCE) of 39.4% for FY26.

Strategic Initiatives and Capex

Clean Science incurred approximately ₹1,000 crore in capital expenditure during Q1FY27, primarily invested in Clean Fino-Chem Limited. The company is establishing a wholly-owned subsidiary in the Netherlands, potentially named Clean Science BV, with an initial capital infusion of EUR 50,000. This entity will focus on distributing specialty chemicals in Europe, strengthening customer proximity and accelerating global growth. Additionally, Performance Chemical 2 is expected to be commercialized by Q3FY27.

What the Numbers Show

The company’s strategy of diversifying through subsidiaries is yielding tangible results. While the parent entity faced margin compression due to higher input costs, the consolidated group achieved record sales. The strategic collaboration with Swiss technology partner Geneus Chem AG has helped de-risk product concentration; the top four legacy products’ contribution declined from ~85% in Q4FY23 to ~60% in Q1FY27. HALS now accounts for 22% of sales, indicating successful portfolio expansion into high-value specialty chemicals.